Literature DB >> 33259771

Synthetic versus Biologic Mesh for Complex Open Ventral Hernia Repair: A Pilot Randomized Controlled Trial.

Oscar A Olavarria1,2, Karla Bernardi1,2, Naila H Dhanani1,2, Nicole B Lyons1, John A Harvin1,2, Stefanos G Millas1, Tien C Ko1, Lillian S Kao1,2, Mike K Liang1,2.   

Abstract

Background: Many surgeons utilize biologic mesh for elective complex ventral hernia repair (VHR; large hernias, contaminated fields, or patients with comorbid conditions). However, no randomized controlled trials (RCTs) have compared biologic and synthetic mesh. We hypothesize biologic mesh would result in fewer major complications at one-year post-operative compared with synthetic mesh. Patients and
Methods: We performed a single-center, pilot RCT. All eligible patients undergoing complex, open VHR were randomly assigned to receive biologic or synthetic mesh placed in the retromuscular position. Primary outcome was major complications, namely, a composite of mesh infection, recurrence, or re-operation at one-year post-operative. Secondary outcomes included surgical site infections (SSI), seromas, hematomas, wound dehiscence, re-admissions, and Clavien-Dindo complication grade. Outcomes were assessed using Fisher exact test and Bayesian generalized linear models.
Results: Of 87 patients, 44 were randomly assigned to biologic mesh and 43 to synthetic mesh. Most cases were wound class 2-4 (68%) and 75% had a hernia width >4 cm. Most patients were obese (70%) and had an American Society of Anesthesiogists (ASA) score of 3-4 (53%). Compared with patients in the synthetic mesh group, patients in the biologic mesh group had a higher percentage of: major complications at one-year post-operative (42.4% vs. 21.6%; relative risk [RR] = 1.96 [95% confidence interval {CI} = 0.94-4.08]; number needed to harm = 4.8; p = 0.071); SSI (15.9% vs. 9.3%; RR = 1.71 [95% CI = 0.54-5.42]; p = 0.362); wound dehiscence (25.0% vs. 14.0%; RR = 1.79 [95% CI = 0.73-4.41]; p = 0.205); and re-admissions (22.7% vs 9.3%; RR = 2.44 [95% CI = 0.83-7.20]; p = 0.105). Bayesian analysis demonstrated that compared with synthetic mesh, biologic mesh had a 95% probability of increased risk of major complications at one-year post-operative. No clear evidence of a difference was found on seromas, hematomas, or Clavien-Dindo complication grade. Conclusions: In elective complex open VHR, biologic mesh demonstrated no benefit compared with synthetic mesh in one-year outcomes. Moreover, Bayesian analysis suggests that biologic mesh may have an increased probability of major complications.

Entities:  

Keywords:  biologic mesh; polypropylene; randomized controlled trial; synthetic mesh; ventral hernia repair

Mesh:

Substances:

Year:  2020        PMID: 33259771      PMCID: PMC8349713          DOI: 10.1089/sur.2020.166

Source DB:  PubMed          Journal:  Surg Infect (Larchmt)        ISSN: 1096-2964            Impact factor:   1.853


  28 in total

1.  A comparison of suture repair with mesh repair for incisional hernia.

Authors:  R W Luijendijk; W C Hop; M P van den Tol; D C de Lange; M M Braaksma; J N IJzermans; R U Boelhouwer; B C de Vries; M K Salu; J C Wereldsma; C M Bruijninckx; J Jeekel
Journal:  N Engl J Med       Date:  2000-08-10       Impact factor: 91.245

2.  Primary Fascial Closure During Laparoscopic Ventral Hernia Repair Improves Patient Quality of Life: A Multicenter, Blinded Randomized Controlled Trial.

Authors:  Karla Bernardi; Oscar A Olavarria; Julie L Holihan; Lillian S Kao; Tien C Ko; John S Roth; Shawn Tsuda; Khashayar Vaziri; Mike K Liang
Journal:  Ann Surg       Date:  2020-03       Impact factor: 12.969

3.  How much loss to follow-up is acceptable in long-term randomised trials and prospective studies?

Authors:  Mary S Fewtrell; Kathy Kennedy; Atul Singhal; Richard M Martin; Andy Ness; Mijna Hadders-Algra; Berthold Koletzko; Alan Lucas
Journal:  Arch Dis Child       Date:  2008-06       Impact factor: 3.791

Review 4.  Mesh Location in Open Ventral Hernia Repair: A Systematic Review and Network Meta-analysis.

Authors:  Julie L Holihan; Duyen H Nguyen; Mylan T Nguyen; Jiandi Mo; Lillian S Kao; Mike K Liang
Journal:  World J Surg       Date:  2016-01       Impact factor: 3.352

Review 5.  Ventral Hernia Repair: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Julie L Holihan; Craig Hannon; Christopher Goodenough; Juan R Flores-Gonzalez; Kamal M Itani; Oscar Olavarria; Jiandi Mo; Tien C Ko; Lillian S Kao; Mike K Liang
Journal:  Surg Infect (Larchmt)       Date:  2017-05-30       Impact factor: 2.150

6.  Epidemiology and cost of ventral hernia repair: making the case for hernia research.

Authors:  B K Poulose; J Shelton; S Phillips; D Moore; W Nealon; D Penson; W Beck; M D Holzman
Journal:  Hernia       Date:  2011-09-09       Impact factor: 4.739

7.  Long-term follow-up of a randomized controlled trial of suture versus mesh repair of incisional hernia.

Authors:  Jacobus W A Burger; Roland W Luijendijk; Wim C J Hop; Jens A Halm; Emiel G G Verdaasdonk; Johannes Jeekel
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

8.  Cost of ventral hernia repair using biologic or synthetic mesh.

Authors:  Crystal F Totten; Daniel L Davenport; Nicholas D Ward; J Scott Roth
Journal:  J Surg Res       Date:  2016-03-04       Impact factor: 2.192

9.  Outcomes with porcine acellular dermal matrix versus synthetic mesh and suture in complicated open ventral hernia repair.

Authors:  Mike K Liang; Rachel L Berger; Mylan Thi Nguyen; Stephanie C Hicks; Linda T Li; Mimi Leong
Journal:  Surg Infect (Larchmt)       Date:  2014-09-12       Impact factor: 2.150

10.  Design and implementation of the Americas Hernia Society Quality Collaborative (AHSQC): improving value in hernia care.

Authors:  B K Poulose; S Roll; J W Murphy; B D Matthews; B Todd Heniford; G Voeller; W W Hope; M I Goldblatt; G L Adrales; M J Rosen
Journal:  Hernia       Date:  2016-03-02       Impact factor: 4.739

View more
  1 in total

1.  Biologic vs Synthetic Mesh for Single-stage Repair of Contaminated Ventral Hernias: A Randomized Clinical Trial.

Authors:  Michael J Rosen; David M Krpata; Clayton C Petro; Alfredo Carbonell; Jeremy Warren; Benjamin K Poulose; Adele Costanzo; Chao Tu; Jeffrey Blatnik; Ajita S Prabhu
Journal:  JAMA Surg       Date:  2022-04-01       Impact factor: 16.681

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.